Press Releases

News Brief

Samsung Biologics attends CITIC CLSA Investors’ Forum

Samsung Biologics attends CITIC CLSA Investors’ Forum
 
Samsung Biologics took part in the 30th CITIC CLSA Investors’ Forum in Hong Kong earlier this month. 

 

Organized by CLSA, a leading institutional brokerage and investment group, and its parent company CITIC Securities, the Investors’ Forum is Asia’s largest investor conference, providing a platform for companies to deliver their growth strategies to the global investment community, exchange insights, and build meaningful relationships with investors.

 

Samsung Biologics was invited to the forum amid strong interest and continuous inquiries from global investors. The Company presented its vision and strategies, and shared its expansion plans during the event.

 

Over 1,000 senior executives from some 320 companies attended this year’s event for meetings with more than 1,800 investors.

Samsung Biologics attends CITIC CLSA Investors’ Forum
 
Samsung Biologics took part in the 30th CITIC CLSA Investors’ Forum in Hong Kong earlier this month. 

 

Organized by CLSA, a leading institutional brokerage and investment group, and its parent company CITIC Securities, the Investors’ Forum is Asia’s largest investor conference, providing a platform for companies to deliver their growth strategies to the global investment community, exchange insights, and build meaningful relationships with investors.

 

Samsung Biologics was invited to the forum amid strong interest and continuous inquiries from global investors. The Company presented its vision and strategies, and shared its expansion plans during the event.

 

Over 1,000 senior executives from some 320 companies attended this year’s event for meetings with more than 1,800 investors.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION